Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? BioPharma DiveWhile many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.OncologyRead full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioPharma Dive While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen’s salanersen gains FDA breakthrough therapy designation for SMANext: Stakeholders want Makary’s voucher program paused, call for FDA independence Related Stories Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026 Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis pharminent July 9, 2026
